MYCN and uveal melanoma: NVP-2, MC180295, fadraciclib, KB-0742, LZT-106, and 21e have been developed, and the inhibitory effects of NVP-2 on BRAFwt/NRASwt/NF1wt cutaneous and uveal melanomas, MC180295 on CRC, fadraciclib on MYCN-amplified Kelly NB tumor, KB-0742 on Pca, LZT-106 on CRC, and 21e on NSCLC, have been reported.